New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing.
about
Very Early-Onset Inflammatory Manifestations of X-Linked Chronic Granulomatous Disease.Efficacy of lentiviral mediated gene therapy in an Omenn syndrome Rag2 mouse model is not hindered by inflammation and immune dysregulation.Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.
P2860
New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
New frontiers in the therapy o ...... gene addition to gene editing.
@en
New frontiers in the therapy o ...... gene addition to gene editing.
@nl
type
label
New frontiers in the therapy o ...... gene addition to gene editing.
@en
New frontiers in the therapy o ...... gene addition to gene editing.
@nl
prefLabel
New frontiers in the therapy o ...... gene addition to gene editing.
@en
New frontiers in the therapy o ...... gene addition to gene editing.
@nl
P2860
P1476
New frontiers in the therapy o ...... gene addition to gene editing.
@en
P2093
Caroline Y Kuo
Donald B Kohn
P2860
P304
P356
10.1016/J.JACI.2017.01.007
P407
P577
2017-03-01T00:00:00Z